100 related articles for article (PubMed ID: 11709501)
1. The continuing tale of cytokeratins in Barrett's mucosa: as you like it.
Latchford A; Eksteen B; Jankowski J
Gut; 2001 Dec; 49(6):746-7. PubMed ID: 11709501
[No Abstract] [Full Text] [Related]
2. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
[TBL] [Abstract][Full Text] [Related]
3. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
4. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
5. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
6. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry.
Sarbia M; Donner A; Franke C; Gabbert HE
Hum Pathol; 2004 Mar; 35(3):371-6. PubMed ID: 15017595
[TBL] [Abstract][Full Text] [Related]
7. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma.
Ormsby AH; Goldblum JR; Rice TW; Richter JE; Gramlich TL
Histopathology; 2001 Apr; 38(4):307-11. PubMed ID: 11318895
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte antigen as a marker of intestinal metaplasia.
Chu PG; Jiang Z; Weiss LM
Am J Surg Pathol; 2003 Jul; 27(7):952-9. PubMed ID: 12826887
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin and CDX-2 expression in Barrett's esophagus.
van Baal JW; Bozikas A; Pronk R; Ten Kate FJ; Milano F; Rygiel AM; Rosmolen WD; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Scand J Gastroenterol; 2008; 43(2):132-40. PubMed ID: 18224560
[TBL] [Abstract][Full Text] [Related]
10. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
Ozcan HEA; Anuk T; Ozden O
Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
[TBL] [Abstract][Full Text] [Related]
11. [Biopsy methods and pathology of Barrett's esophagus].
Takubo K; Honma N; Sawabe M; Arai T; Tanaka Y; Kino K; Iwakiri K
Nihon Rinsho; 2005 Aug; 63(8):1429-33. PubMed ID: 16101234
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens.
El-Zimaity HM; Graham DY
Am J Gastroenterol; 2001 May; 96(5):1378-82. PubMed ID: 11374671
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratins 7 and 20 and mucin core protein expression in esophageal cervical inlet patch.
Lauwers GY; Mino M; Ban S; Forcione D; Eatherton DE; Shimizu M; Sevestre H
Am J Surg Pathol; 2005 Apr; 29(4):437-42. PubMed ID: 15767795
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
15. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
16. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
Wang R; Xie J; Shen Y; Ren T
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
[TBL] [Abstract][Full Text] [Related]
17. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
19. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG
Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144
[TBL] [Abstract][Full Text] [Related]
20. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line.
Konturek PC; Burnat G; Rau T; Hahn EG; Konturek S
Dig Dis Sci; 2008 Mar; 53(3):597-605. PubMed ID: 17763959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
